PT  - JOURNAL ARTICLE
AU  - Ghisolfi, Selene
AU  - Almås, Ingvild
AU  - Sandefur, Justin
AU  - von Carnap, Tillmann
AU  - Heitner, Jesse
AU  - Bold, Tessa
TI  - Predicted COVID-19 fatality rates based on age, sex, comorbidities, and health system capacity
AID  - 10.1101/2020.06.05.20123489
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.05.20123489
4099  - http://medrxiv.org/content/early/2020/06/07/2020.06.05.20123489.short
4100  - http://medrxiv.org/content/early/2020/06/07/2020.06.05.20123489.full
AB  - Early reports suggest the fatality rate from COVID-19 varies greatly across countries, but non-random testing and incomplete vital registration systems render it impossible to directly estimate the infection fatality rate (IFR) in many low- and middle-income countries. To fill this gap, we estimate the adjustments required to extrapolate estimates of the IFR from high- to lower-income regions. Accounting for differences in the distribution of age, sex, and relevant comorbidities yields substantial differences in the predicted IFR across 21 world regions, ranging from 0.11% in Western Sub-Saharan Africa to 0.95% for High Income Asia Pacific. However, these predictions must be treated as lower bounds, as they are grounded in fatality rates from countries with advanced health systems. In order to adjust for health system capacity, we incorporate regional differences in the relative odds of infection fatality from childhood influenza. This adjustment greatly diminishes, but does not entirely erase, the demography-based advantage predicted in the lowest income settings, with regional estimates of the predicted COVID-19 IFR ranging from 0.43% in Western Sub-Saharan Africa to 1.74% for Eastern Europe.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSandefur acknowledges external support to the Center for Global Development from the Bill and Melinda Gates Foundation for global health research. All author authors report no external support for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Data utilized was from publicly available sources with no individual level identifiers. The authors self-exempted the data as not qualifying as human subjects research requiring IRB oversight.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe analysis relies on the following, publicly available data sources. Administrative reports from the Italian Istituto Superiore di Sanita: https://www.epicentro.iss.it/coronavirus/sars-cov-2-decessi-italia Administrative reports from NYC Health: https://www1.nyc.gov/assets/doh/downloads/pdf/imm/covid-19-daily-data-summary-deaths-05162020-1.pdf Global Burden of Disease data: http://ghdx.healthdata.org/gbd-2017 Supplementary material reported in Salje et al (Science, 2020): https://science.sciencemag.org/content/sci/suppl/2020/05/12/science.abc3517.DC1/abc3517_Salje_SM.pdf